SynthesisFrontiers in oncology2023
An updated systemic review and meta-analysis on human papillomavirus in breast carcinogenesis.
Synthesis in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The oncogenic role of human papillomavirus in breast cancer: a comprehensive systematic review and meta-analysis.Frontiers in microbiology · 2025Pooled it
- Prevalence and genotypic distribution of high-risk human papillomavirus in primary breast tumors in Western Uganda: a case-control study.Scientific reports · 2026Article
- Absence of high-risk human papillomavirus in breast cancer tissues from young BRCA1/BRCA2-negative women.BMC women's health · 2026Article
- Accelerating Evidence Synthesis: A BERT-Assisted Workflow for Meta-Analyses of Radiotherapy Complications in Nasopharyngeal Carcinoma.Reports (MDPI) · 2026Article
- Predicting radiological regression in benign breast hyperplasia: the prolactin-to-estradiol ratio as a prognostic biomarker.Frontiers in medicine · 2026Article
- Unveiling the inhibitory effects of tannic acid and doxorubicin combination on pyruvate kinase M2 in breast cancer cells.Frontiers in pharmacology · 2026Article
- Human papilloma virus as causal in breast cancer.Frontiers in oncology · 2026Review
- Risk-stratified surveillance after LEEP: a nomogram integrating HPV persistence, margin status, and clinical factors to predict CIN2+ recurrence.Frontiers in oncology · 2026Article
- Decoding the relationships among miRNA, HPV infection, and tumor suppressor gene expression in breast cancer patients.Scientific reports · 2025Article
- HPV-driven breast carcinogenesis: associations with tumor severity, Ki67 expression and metastasis.Infectious agents and cancer · 2025Article
- Detection ofInfection and drug resistance · 2025Article
- Population-level barriers to home hemodialysis implementation: a public health systems analysis of adoption readiness, health equity, and policy implications in China.Frontiers in public health · 2025Article
- Review
- The viral origins of breast cancer.Infectious agents and cancer · 2024Review
- Article
- Assessing perceptions of nursing knowledge, attitudes, and practices in diabetes management within Chinese healthcare settings.Frontiers in public health · 2024Article
- An exploratory study of knowledge, attitudes, and practices toward HPV associated anal cancer among Pakistani population.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast Cancer (BC) stands out as the widely prevalent malignancy among all the types of cancer affecting women worldwide. There is significant evidence that the pathogenicity of BC may be altered by Human Papillomavirus (HPV) infection; however, conclusive data are not yet available. Methods: By searching five databases, including EMBASE, IBECS, PubMed, Scopus, Science Direct, Google Scholar, and Web of Science, a thorough systematic analysis was conducted on the prevalence of HPV in BC patients from 1990 to June 30, 2022. After applying extensive eligibility criteria, we selected 74 publications for further analysis based on the prevalence of HPV infections in breast tissues. All of the data were analyzed using a random-effects meta-analysis, Cochran Q test and Results: In total, 3156 studies were initially screened, resulting in 93 full-text studies reviewed, with 74 meeting inclusion criteria. Among a total of 7156 BC biopsies, the pool prevalence of HPV was 25.6% (95% CI= 0.24-0.33, τ2 = 0.0369 with significant heterogeneity between estimates ( Conclusion: Current study provides a global estimate of HPV prevalence in BC patients and demonstrates a significant association between this virus and BC etiology. Nevertheless, we recommend further investigation into the underlying mechanism is essential to validate this hypothesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.